ERBB2 and triple-negative breast carcinoma: HER2-positive (HER2+) and triple-negative breast cancers (TNBC) exhibit the most unfavorable prognosis, primarily attributable to the intrinsic resistance or acquired insensitivity of certain HER2+ tumors to anti-HER2 therapies, as well as the unresponsiveness of TNBC to hormonal therapies or agents targeting HER2 receptors [6].